Connect with us

Self-Sufficient Living Portal

Self-Sufficient Living Portal

Coronavirus stock These are the 5 scientists and executives getting the richest off Moderna’s spike to record highs (MRNA)


News

Coronavirus stock These are the 5 scientists and executives getting the richest off Moderna’s spike to record highs (MRNA)

David L. Ryan/The Boston Globe/Getty Images Moderna’s 30% gain in Monday trading is making a small group of scientists and executives a fortune. The biotech company surged after announcing phase-one trials of its coronavirus vaccine successfully produced antibodies in all 45 participants.Moderna now plans to finalize phase-three studies in July before bringing its vaccine to…

Coronavirus stock

David L. Ryan/The Boston Globe/Getty Images

  • Moderna’s 30% gain in Monday trading is making a small group of scientists and executives a fortune.
  • The biotech company surged after announcing phase-one trials of its coronavirus vaccine successfully produced antibodies in all 45 participants.
  • Moderna now plans to finalize phase-three studies in July before bringing its vaccine to market in the fall.
  • Here are the five Moderna shareholders poised to make the most from its soaring stock price.
  • Watch Moderna trade live here.

Moderna stock soared to record highs on Monday, minting new fortunes for a small group of executives and scientists.

The biotech company’s shares launched as much as 30%, or about $20, higher on Monday after it revealed its coronavirus vaccine’s phase-one results. The experimental drug successfully produced antibodies in all 45 volunteers, Moderna said. The company plans to begin phase-three trials in July and roll out a vaccine for emergency use in the fall.

The positive results lifted the market as well, with the S&P 500 leaping as much as 3.4% in Monday trading.

“We could not be happier with this interim data,” CEO Stephane Bancel said in a Monday call with analysts.

Some analysts think the stock still has room to run as its critical vaccine moves further into trials. Goldman Sachs lifted its Moderna price target to a Wall Street high of $105 from $63 on Monday, saying “encouraging” phase-one results improved the drug’s likelihood of approval.

Here are the five Moderna shareholders set to win the most from the surging stock price, ranked in ascending order of shares owned. Shareholder data is sourced from Bloomberg.

Read more:A Wall Street equity chief lays out 5 reasons why another ‘significant drawdown’ in stocks is coming right after the fastest crash in history



5. Lorence Kim

David L. Ryan/The Boston Globe via Getty Images

Role: Chief financial officer

Shares held: 1,222,510

Stake value: $97,800,800



4. Stephen Hoge

Moderna/YouTube

The Most Powerful Sale & Affiliate Platform Available!

There's no credit card required! No fees ever.

Create Your Free Account Now!

Role: President

Shares held: 2,010,656

Stake value: $160,852,480



2. Stephane Bancel

Andrew Harnik/AP Images

Role: CEO

Shares held: 7,348,167

Stake value: $587,853,360


Subscribe to the newsletter news

We hate SPAM and promise to keep your email address safe

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Top Stories

Self-Sufficiency Living

To Top